3.1587

1.89% -0.0113

Recursion Pharmaceuticals Inc (RXRX)

Overview News Price History Option Chain Financials Why RXRX Down? Discussions Forecast

Recursion Pharmaceuticals Inc stock is traded at $3.1587, with a volume of 865.41K. It is down -1.89% in the last 24 hours and down -17.51% over the past month. Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.

Previous Close:

$3.17

Open:

$3.095

24h Volume:

865.41K

Relative Volume:

0.04

Market Cap:

$1.67B

Revenue:

$74.68M

Net Income/Loss:

$-644.76M

P/E Ratio:

-2.1301

EPS:

-1.4829

Net Cash Flow:

$-380.44M

1W Performance:

-7.72%

1M Performance:

-17.51%

6M Performance:

-34.11%

1Y Performance:

-49.59%

1-Day Range:

$3.095

$3.175

1-Week Range:

$3.08

$3.42

52-Week Range:

$2.98

$7.18

Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile

Name

Recursion Pharmaceuticals Inc

Sector

Healthcare (1115)

Industry

Biotechnology (623)

Phone

(385) 269-0203

Address

41S RIO GRANDE STREET, SALT LAKE CITY

Employee

600

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

RXRX's Discussions on Twitter

Compare RXRX vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RXRX Recursion Pharmaceuticals Inc	3.165	1.67B	74.68M	-644.76M	-380.44M	-1.4829
VRTX Vertex Pharmaceuticals Inc	452.50	115.58B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	752.21	79.23B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.13	43.59B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	692.41	43.26B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	147.84	31.97B	606.42M	-1.28B	-997.58M	-6.403

Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-17-25	Upgrade	JP Morgan	Neutral → Overweight
Jul-03-25	Resumed	Morgan Stanley	Equal-Weight
May-22-23	Initiated	Morgan Stanley	Equal-Weight
Mar-16-23	Initiated	Needham	Buy
Sep-16-22	Initiated	KeyBanc Capital Markets	Overweight
Apr-18-22	Downgrade	BofA Securities	Buy → Neutral
Mar-04-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Sep-21-21	Initiated	Berenberg	Buy
May-11-21	Initiated	BofA Securities	Buy
May-11-21	Initiated	Goldman	Neutral
May-11-21	Initiated	JP Morgan	Neutral
May-11-21	Initiated	KeyBanc Capital Markets	Overweight
May-11-21	Initiated	SVB Leerink	Outperform

View All

Recursion Pharmaceuticals Inc Stock (RXRX) Latest News

04:53 AM

Recursion Pharmaceuticals Appoints Vicki Goodman, M.D. as Chief Medical Officer to Advance Clinical Pipeline and AI-Driven Drug Development 1 - Minichart

04:53 AM

Mar 25, 2026

Recursion Pharmaceuticals | 8-K: Current report - Moomoo

Mar 25, 2026

Recursion Pharmaceuticals Names New Chief Medical Officer - TipRanks

Mar 25, 2026

Recursion appoints Vicki Goodman as Chief Medical Officer; David Mauro to transition to advisor - TradingView

Mar 25, 2026

EXEL: Former Executive Joins Recursion Pharmaceuticals as New CM - GuruFocus

Mar 25, 2026

Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer - marketscreener.com

Mar 25, 2026

Mar 24, 2026

Assessing Recursion Pharmaceuticals (RXRX) Valuation After Prolonged Share Price Weakness - Sahm

Mar 24, 2026

Recursion Pharmaceuticals Stock (RXRX) Opinions on Roche's AI Drug Development Commitment - Quiver Quantitative

Mar 24, 2026

Mar 23, 2026

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo

Mar 23, 2026

Mar 22, 2026

Prediction: The "Trough of Disillusionment" Will Create the Best Buying Opportunity for Artificial Intelligence (AI) Stocks in 2026 - The Motley Fool

Mar 22, 2026

Recursion Pharmaceuticals Details AI-Driven Drug Pipeline, Sanofi/Roche Milestones, Runway to 2028 - MarketBeat

Mar 22, 2026

Mar 19, 2026

Recursion’s Khan: AI will be judged by the medicines it makes - BioCentury

Mar 19, 2026

Recursion Pharmaceuticals (RXRX) Advances While Market Declines: Some Information for Investors - Yahoo Finance

Mar 19, 2026

Mar 18, 2026

What makes Recursion Pharmaceuticals (RXRX) so attractive - MSN

Mar 18, 2026

Ben Taylor Sells 7,956 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock - MarketBeat

Mar 18, 2026

Recursion Pharma CFO Taylor sells $26970 in shares - Investing.com

Mar 18, 2026

CFO of Recursion Pharmaceuticals (RXRX) sells 7,956 shares under 10b5-1 plan - Stock Titan

Mar 18, 2026

Recursion Pharmaceuticals sets post-hype agenda at LeerinkPartners healthcare event - Traders Union

Mar 18, 2026

BofA lowers PT on Recursion Pharmaceuticals (RXRX), keeps a hold rating - MSN

Mar 18, 2026

Mar 16, 2026

Jim Cramer on Recursion Pharmaceuticals: “It’s a let down, big let down” - MSN

Mar 16, 2026

Mar 15, 2026

Why Recursion Pharmaceuticals, Inc. (RXRX)'s upside case hasn't fully convinced yet - MSN

Mar 15, 2026

Mar 14, 2026

RXRX SEC FilingsRecursion Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 14, 2026

Is Recursion Pharmaceuticals, Inc. (RXRX) the best fundamentally strong penny stock to buy? - MSN

Mar 14, 2026

Costco, AMD, Recursion Pharmaceuticals, Cipher Mining And Snowflake: Why These 5 Stocks Are On Investors' Radars Today - AOL.com

Mar 14, 2026

Mar 13, 2026

Measuring the AI Bubble - Pharmaceutical Executive

Mar 13, 2026

Jim Cramer on Recursion Pharmaceuticals: “It’s a Let Down, Big Let Down” - Insider Monkey

Mar 13, 2026

A Look At Recursion Pharmaceuticals (RXRX) Valuation After Q4 Beat And AI Clinical Progress - Sahm

Mar 13, 2026

Mar 12, 2026

PARG inhibitors disclosed in Recursion Pharmaceuticals patent - BioWorld MedTech

Mar 12, 2026

Mar 11, 2026

Recursion Pharmaceuticals and Applied Digital shares fall after Nvidia exits stakes - MSN

Mar 11, 2026

Needham Retains Buy Rating on Recursion Pharmaceuticals, Maintains PT at $8 - MSN

Mar 11, 2026

Recursion Pharmaceuticals (NASDAQ:RXRX) CEO Sells $94,798.30 in Stock - MarketBeat

Mar 11, 2026

Recursion (NASDAQ: RXRX) director converts 20K Class B, gifts 20K A - Stock Titan

Mar 11, 2026

Jim Cramer on Recursion: “It is so low that it comes in under the category of speculative” - MSN

Mar 11, 2026

Mar 10, 2026

Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance

Mar 10, 2026

Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Recent 1‑Year Share Slump Accurately - Yahoo Finance

Mar 10, 2026

How Recursion’s AI Proof of Concept and Equity Raise Will Impact Recursion Pharmaceuticals (RXRX) Investors - Yahoo Finance

Mar 10, 2026

A Look At Recursion Pharmaceuticals (RXRX) Valuation After AI Milestone And Improved Quarterly Results - Yahoo Finance

Mar 10, 2026

Mar 09, 2026

Recursion’s First AI Clinical Proof Links Pipeline Progress With Valuation Gap - Yahoo Finance

Mar 09, 2026

Day Trade: Why retail investors pile into Recursion Pharmaceuticals Inc. stockTrade Analysis Summary & Community Supported Trade Ideas - Naître et grandir

Mar 07, 2026

symbol__ Stock Quote Price and Forecast - CNN

Mar 07, 2026

10 Low Risk Penny Stocks to Buy Now - Insider Monkey

Mar 07, 2026

Mar 06, 2026

Recursion Pharmaceuticals’ Earnings Call Highlights AI Momentum - TipRanks

Mar 06, 2026

Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia - MSN

Mar 06, 2026

BoFA Lowers PT on Recursion Pharmaceuticals (RXRX), Keeps a Hold Rating - Insider Monkey

Mar 06, 2026

Assessing Recursion Pharmaceuticals (RXRX) Valuation After Earnings Jump And New Equity Offering Plans - Sahm

Mar 06, 2026

Mar 05, 2026

ARK Investment Management LLC Purchases 556,868 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat

Mar 05, 2026